Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Apr;173(1):105-13.
doi: 10.1111/bjh.13933. Epub 2016 Feb 5.

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience

Daniel L Van Dyke  1 , Lillian Werner  2 , Laura Z Rassenti  3 , Donna Neuberg  2 , Emanuella Ghia  3 , Nyla A Heerema  4 , Paola Dal Cin  5 , Marie Dell Aquila  3 , Chandrika Sreekantaiah  6 , Andrew W Greaves  3 , Thomas J Kipps  3 , Neil E Kay  1
Affiliations
Clinical Trial

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience

Daniel L Van Dyke et al. Br J Haematol. 2016 Apr.

Abstract

This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well-documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.

Keywords: chronic lymphocytic leukaemia; cytogenetics; fluorescence in situ hybridization; leukaemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time to first treatment and overall survival by FISH category for patients who had FISH analysis less than 4 years after diagnosis of chronic lymphocytic leukaemia. FISH, fluorescence in situ hybridization; Dx, diagnosis.
Figure 2
Figure 2
Time to first treatment and overall survival by FISH category from the date when FISH analysis was done. FISH, fluorescence in situ hybridization.
Figure 3
Figure 3
Association of percentage of 13q deletion nuclei and TTFT from when FISH analysis was done. FISH, fluorescence in situ hybridization; TTFT, time to first treatment.
Figure 4
Figure 4
Association of percentage of 17p deletion nuclei and TTFT from when FISH analysis was done. FISH, fluorescence in situ hybridization; TTFT, time to first treatment.
See this image and copyright information in PMC

References

    1. Baliakas, P. , Hadzidimitriou, A. , Sutton, L.A. , Rossi, D. , Minga, E. , Villamor, N. , Larrayoz, M. , Kminkova, J. , Agathangelidis, A. , Davis, Z. , Tausch, E. , Stalika, E. , Kantorova, B. , Mansouri, L. , Scarfo, L. , Cortese, D. , Navrkalova, V. , Rose‐Zerilli, M.J. , Smedby, K.E. , Juliusson, G. , Anagnostopoulos, A. , Makris, A.M. , Navarro, A. , Delgado, J. , Oscier, D. , Belessi, C. , Stilgenbauer, S. , Ghia, P. , Pospisilova, S. , Gaidano, G. , Campo, E. , Strefford, J.C. , Stamatopoulos, K. & Rosenquist, R. (2015) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia, 29, 329–336. - PubMed
    1. Braggio, E. , Kay, N.E. , VanWier, S. , Tschumper, R.C. , Smoley, S. , Eckel‐Passow, J.E. , Sassoon, T. , Barrett, M. , Van Dyke, D.L. , Byrd, J.C. , Jelinek, D.F. , Shanafelt, T.D. & Fonseca, R. (2012) Longitudinal genome‐wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia, 26, 1698–1701. - PMC - PubMed
    1. Chuang, H.Y. , Rassenti, L. , Salcedo, M. , Licon, K. , Kohlmann, A. , Haferlach, T. , Foa, R. , Ideker, T. & Kipps, T.J. (2012) Subnetwork‐based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood, 120, 2639–2649. - PMC - PubMed
    1. Claus, R. , Lucas, D.M. , Ruppert, A.S. , Williams, K.E. , Weng, D. , Patterson, K. , Zucknick, M. , Oakes, C.C. , Rassenti, L.Z. , Greaves, A.W. , Geyer, S. , Wierda, W.G. , Brown, J.R. , Gribben, J.G. , Barrientos, J.C. , Rai, K.R. , Kay, N.E. , Kipps, T.J. , Shields, P. , Zhao, W. , Grever, M.R. , Plass, C. & Byrd, J.C. (2014) Validation of ZAP‐70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood, 124, 42–48. - PMC - PubMed
    1. Dal Bo, M. , Rossi, F.M. , Rossi, D. , Deambrogi, C. , Bertoni, F. , Del Giudice, I. , Palumbo, G. , Nanni, M. , Rinaldi, A. , Kwee, I. , Tissino, E. , Corradini, G. , Gozzetti, A. , Cencini, E. , Ladetto, M. , Coletta, A.M. , Luciano, F. , Bulian, P. , Pozzato, G. , Laurenti, L. , Forconi, F. , Di Raimondo, F. , Marasca, R. , Del Poeta, G. , Gaidano, G. , Foa, R. , Guarini, A. & Gattei, V. (2011) 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes, Chromosomes & Cancer, 50, 633–643. - PubMed

Publication types

MeSH terms